We further show that the expression of Lck in BCR-stimulated TCL1-transgenic CLL cells can be efficiently downregulated using the NFAT peptide inhibitor VIVIT clearly identifying Lck as an NFAT target gene (Fig. 5h). The gene discussed is BCR; the disease is B-cell chronic lymphocytic leukemia.